Sudhakar Selvaraj, MBBS DPhil MRCPsych
Assistant Professor of Psychiatry
University of Texas Health Science Center
SS has received speaking honoraria from Global Medical Education and honoraria from the British Medical Journal Publishing Group. He owns convertible shares at Flow MedTech, Inc (a medical device start-up company). He has been involved in a treatment-resistant depression clinical trial and received research support from COMPASS pathways (a mental healthcare company).
Dr Sudhakar Selvaraj would like to gratefully acknowledge Dr Prashant Gajwani and Dr David J. Muzina, previous contributors to this topic.
PG has served on the speakers' bureau for Merck and Sunovion. DJM is an author of a number of references cited in this topic. DJM has previously received honoraria for research support from Repligen Co. He has also previously received honoraria as a speaker and/or advisor from AstraZeneca, Pfizer, BMS, Wyeth, Sepracor, and GSK. DJM is a full-time employee of Medco.
Roger McIntyre, MD
Mood Disorders Psychopharmacology Unit
University Health Network
Associate Professor of Psychiatry and Pharmacology
University of Toronto
RM has received research funds from Stanley Medical Research Institute and National Alliance for Research on Schizophrenia and Depression (NARSAD). RM is on the advisory boards for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. RM is on the speakers' bureau for Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck, Biovail, and Wyeth. RM has received research grants from Eli Lilly, Janssen-Ortho, and Shire.
Jan Scott, MBBS
Professor of Psychological Medicine
University of Newcastle
Psychological Treatments Research
Institute of Psychiatry
University Department of Psychiatry
Royal Victoria Infirmary
Newcastle upon Tyne
JS has received remuneration for attending advisory boards for AstraZeneca, BSM-Otsuka, Eli Lilly, GSK, and Sanofi-Aventis.